Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma

BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarke...

詳細記述

保存先:
書誌詳細
出版年:Br J Cancer
主要な著者: Werner, Thomas A, Tamkan-Ölcek, Yasemin, Dizdar, Levent, Riemer, Jasmin C, Wolf, Achim, Cupisti, Kenko, Verde, Pablo E, Knoefel, Wolfram T, Krieg, Andreas
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2016
主題:
Translational Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815780/
https://ncbi.nlm.nih.gov/pubmed/26882066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料